PharmaEssentia Company Description

PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan.

Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias.

The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and immunology.

PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.

PharmaEssentia Corporation

Country	Taiwan
Founded	1990
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	131
CEO	Ko-Chung Lin

Contact Details

Address: No. 3, Park Street Taipei, 115 Taiwan
Phone	886 2 2655 7688
Website	pharmaessentia.com

Stock Details

Ticker Symbol	6446
Exchange	Taiwan Stock Exchange
Fiscal Year	January - December
Reporting Currency	TWD
ISIN Number	TW0006446008
SIC Code	2836

Key Executives

Name	Position
Ko-Chung Lin Ph.D.	Founder, Chief Executive Officer, Chief Strategy Officer and Director
Dr. Ching-Leou Teng Ph.D.	Chairman and Chief Pharmaceutical Officer
Chan-Kou Hwang Ph.D.	President, GM and Director
Snow Chang	Director of Finance
Samuel Lin	Vice President and Head of Business Operations and Strategy
Lih-Ling Lin Ph.D.	Chief Scientific Officer
Hsing-I Chen	General Counsel
Dr. Albert Qin M.D., Ph.D.	Chief Medical Officer
Narihisa Miyachi	Head of Japan Medical Affairs
Yen-Tung Luan	Chief Operating Officer of Taichung Plant